About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
Grand Pharma Announced Annual Results for the Year Ended 31 December 2023
2024-03-22

Financial summary

– For the year ended 31 December 2023 (the “Year”), the business of the Group grew steadily and recorded a revenue of approximately HK$10,529.59 million (2022: HK$9,562.29 million), representing a year-on-year increase of approximately 10.1%. If disregarding the impact of exchange rate fluctuation between RMB and HK$, it was increased by approximately 15.8% as compared with the same period in 2022.

– The gross profit of the Group was approximately HK$6,524.07 million (2022: HK$5,951.48 million), representing a year-on-year increase of approximately 9.6%. If disregarding the impact of exchange rate fluctuation between RMB and HK$, it was increased by approximately 15.3% as compared with the same period in 2022.

– The normalized profit for the Year attributable to the owners of the Company was approximately RMB 2,036.24 million, a decrease of approximately 4.7% compared to the same period last year. If disregarding the impact of exchange rate fluctuation between RMB and HK$, it would have increased by approximately 0.2% compared with the same period in 2022.

– It is the objective of the Group to share the operating results of the Group and protect the shareholders’ interests. Based on the good performance during the Year, the board of directors recommends the payment of a final dividend of 26 cents per share, totaling amounted to approximately HK$905.14 million.

– During the Year, the Group continued to invest in ongoing research projects and the introduction of innovative projects. The Group’s investment in research and development work and projects, including the research and development expenses, capitalized research and development expenses, prepayments for new projects and other investments, was approximately HK$1,441.00 million.

Read more here: https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0320/2024032000001.pdf

Prev

Next

Related news

  • The Phase II Clinical Trial in China of Grand Pharma’s Class 1 Innovative Traditional Chinese Medicine GPN01360 Successfully Reaches the Clinical Endpoint
    The Phase II Clinical Trial in China of Grand Pharma’s Class 1 Innovative Traditional Chinese Medicine GPN01360 Successfully Reaches the Clinical Endpoint

    2025-12-09

  • <em>The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment</em>
    The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

    2025-10-26

  • The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment
    The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment

    2025-10-09

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions